Table 1 Baseline clinic-pathological characteristics.
Mean age, years (range) | 76 (54–89) |
|---|---|
PS | |
0 | 49 |
1 | 24 |
2 | 4 |
N/A | 10 |
Pathology | |
Adenocarcinoma | 87 |
ISUP | |
I | 8 |
II | 7 |
III | 18 |
IV | 19 |
V | 33 |
N/A | 2 |
Type of initial management | |
RARP | 6 |
RT | 9 |
DOC upfront | 15 |
Time from initial management to 1. cycle enzalutamide, mo, median (range) | 25 (4–231) |
RARP | 135 (18–231) |
RT | 89 (26–168) |
DOC upfront | 17 (4–25) |
Type of castration treatment | |
Medical | 81 |
Medical then surgical | 6 |
Median PSA level, ng/mL (range) | 50 (1–396) |
Site of metastases* | |
Bone | 73 |
LN | 39 |
Lung | 5 |
Others | 3 |
Time to mCRPC, mo, median (range) | 68 (8–238) |
Follow-up, mo, median (range) | 39 (14–62) |
Time to BP, mo, median (range) | 7 (1–47) |
Time to RP, mo, median (range) | 20 (2–53) |
Death | 42 |
Synchronic cancer | 2 |
Previous Cancer | 7 |
Auto-immune disease | 6 |
